April 2016

New Product - Strensiq

Strensiq (asfotase alfa (rch)) is a human recombinant tissue nonspecific alkaline phosphatase (TNSALP)-Fc-deca-aspartate fusion protein with enzymatic activity. Asfotase alfa promotes mineralisation of the skeleton in hypophosphatasia (HPP). Strensiq is indicated as enzyme replacement therapy in paediatric onset HPP. Asfotase alfa is contraindicated with known hypersensitivity to Chinese hamster ovary cell proteins. Strensiq is available in two strengths, 40 mg/mL (18 mg/0.45 mL, 28 mg/0.7 mL and 40 mg/1 mL single use vials in packs of 12’s) and 100 mg/mL (80 mg/0.8 mL single use vials in packs of 12’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629